About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 8244 record(s)
Req # A-2023-001177
Information and documents submitted by Exegi Pharma, limited liability company (LLC) to Health Canada in 2020 and 2021 seeking a Natural Health Product Licence for the Visbiome Extra Strength product which issued as NPN 80109034.Organization: Health Canada
July 2024
Req # A-2023-001272
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Avapritinib New Drug Submission (NDS).Organization: Health Canada
July 2024
Req # A-2023-001302
The Product Information Template: Regulatory Enrollment Process for the Estradiol Abbreviated New Drug Submission (ANDS), setting out the proposed indication/use of the new drug.Organization: Health Canada
July 2024
Req # A-2023-001307
Records received from and sent to the Government of Alberta, Alberta Health Services (AHS) or parallel Alberta government agencies regarding the exceptional import of children's pain medications into Alberta. Search records between: November 1…Organization: Health Canada
July 2024
Req # A-2023-001325
Correspondence relating to any Abbreviated New Drug Submission (ANDS) filed since January 1, 2022 where the medicinal ingredient is mesalazine and which discuss the dosage form and indication for use.Organization: Health Canada
July 2024
Req # A-2023-001329
Correspondence relating to any Abbreviated New Drug Submission (ANDS) filed since January 1, 2022 where the medicinal ingredient is mesalazine and which discusses the route of administration.Organization: Health Canada
July 2024
Req # A-2023-001331
Advise whether the Mesalazine Abbreviated New Drug Submission (ANDS) has received either: a Screening Acceptance Letter; a Notice of Deficiency (NOD); a Notice of Non-Compliance (NON); a NOD-Withdrawal (NOD-W); or a NON-Withdrawal (NON-W).Organization: Health Canada
July 2024
Req # A-2023-001458
The Product Information Template: Regulatory Enrollment Process for the Third Desmopressin Abbreviated New Drug Submission (ANDS), setting out the proposed indication(s)/use(s) of the drug product.Organization: Health Canada
July 2024
Req # A-2023-001470
The regulatory letter sent to Naked Organs Ltd. in October 2023.Organization: Health Canada
July 2024
Req # A-2023-001481
Documents and records containing information regarding the mock-ups of every label to be used in connection with the Degarelix Abbreviated New Drug Submission (ANDS).Organization: Health Canada
July 2024